Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Avatrombopag in Chemotherapy-Induced Thrombocytopenia
2018-000023-13Phase 3Completed
- Sponsor
- Dova Pharmaceuticals, Inc.
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of avatrombopag in chemotherapy-induced thrombocytopenia (CIT) and Thrombocytopenia (3 arms), sponsored by Dova Pharmaceuticals, Inc. Started Jul 2018; status: completed.
02
Drugs
avatrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)Thrombocytopenia
Beyond the preview
Go deeper on 2018-000023-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000023-13.